In yesterday’s Wall Street session, Catalent Inc. (NYSE:CTLT) shares traded at $43.36, up 0.74% from the previous session.
As of this writing, 16 analysts cover Catalent Inc. (NYSE:CTLT). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $55.00 and a low of $33.00, we find $47.00. Given the previous closing price of $43.04, this indicates a potential upside of 9.2 percent. CTLT stock price is now 6.58% away from the 50-day moving average and -21.76% away from the 200-day moving average. The market capitalization of the company currently stands at $7.32B.
There are 8 analysts who have given it a hold rating, whereas 6 have given it a buy rating. Brokers who have rated the stock have averaged $45.82 as their price target over the next twelve months.
With the price target reduced from $45 to $44, Jefferies Downgraded its rating from Buy to Hold for Catalent Inc. (NYSE: CTLT).
In other news, Boerman Manja, Pres. BioModalities Division sold 1,446 shares of the company’s stock on May 01. The stock was sold for $72,098 at an average price of $49.86. Upon completion of the transaction, the Pres. BioModalities Division now directly owns 14,414 shares in the company, valued at $0.62 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 01, SVP, Ops, Biologics Europe Gargiulo Mario sold 678 shares of the business’s stock. A total of $33,805 was realized by selling the stock at an average price of $49.86. This leaves the insider owning 5,676 shares of the company worth $0.25 million. Insiders disposed of 100,822 shares of company stock worth roughly $4.37 million over the past 1 year. A total of 0.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CTLT stock. A new stake in Catalent Inc. shares was purchased by SENATOR INVESTMENT GROUP LP during the first quarter worth $65,040,000. DURABLE CAPITAL PARTNERS LP invested $64,048,000 in shares of CTLT during the first quarter. In the first quarter, CAPITAL INTERNATIONAL INVESTORS acquired a new stake in Catalent Inc. valued at approximately $60,905,000. POINT72 ASSET MANAGEMENT, L.P. acquired a new stake in CTLT for approximately $54,504,000. LAURION CAPITAL MANAGEMENT LP purchased a new stake in CTLT valued at around $39,885,000 in the second quarter. In total, there are 788 active investors with 105.83% ownership of the company’s stock.
During the past 12 months, Catalent Inc. has had a low of $31.45 and a high of $115.33. As of last week, the company has a debt-to-equity ratio of 1.03, a current ratio of 1.80, and a quick ratio of 1.30. According to the stock market information, the enterprise value for the company is $12.37B, which is based on a 373.79 price-to-earnings ratio, a 88.93 price-to-earnings-growth ratio, and a beta of 1.21. The fifty day moving average price for CTLT is $40.69 and a two-hundred day moving average price translates $55.18 for the stock.
The latest earnings results from Catalent Inc. (NYSE: CTLT) was released for Mar, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.09, missing analysts’ expectations of -$0.03 by -0.06. This compares to $0.78 EPS in the same period last year. The net profit margin was 0.50% and return on equity was 0.40% for CTLT. The company reported revenue of $1.04 billion for the quarter, compared to $1.27 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -18.54 percent. For the current quarter, analysts expect CTLT to generate $1.05B in revenue.
Catalent Inc.(CTLT) Company Profile
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.
